These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 37180996)

  • 1. Predictive blood biomarkers and brain changes associated with age-related cognitive decline.
    Saunders TS; Pozzolo FE; Heslegrave A; King D; McGeachan RI; Spires-Jones MP; Harris SE; Ritchie C; Muniz-Terrera G; Deary IJ; Cox SR; Zetterberg H; Spires-Jones TL
    Brain Commun; 2023; 5(3):fcad113. PubMed ID: 37180996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plaque biogenesis in brain aging and Alzheimer's disease. I. Progressive changes in phosphorylation states of paired helical filaments and neurofilaments.
    Su JH; Cummings BJ; Cotman CW
    Brain Res; 1996 Nov; 739(1-2):79-87. PubMed ID: 8955927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum GFAP levels correlate with astrocyte reactivity, post-mortem brain atrophy and neurofibrillary tangles.
    Sánchez-Juan P; Valeriano-Lorenzo E; Ruiz-González A; Pastor AB; Rodrigo Lara H; López-González F; Zea-Sevilla MA; Valentí M; Frades B; Ruiz P; Saiz L; Burgueño-García I; Calero M; Del Ser T; Rábano A
    Brain; 2024 May; 147(5):1667-1679. PubMed ID: 38634687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of glial fibrillary acid protein, Alzheimer's disease pathology and cognitive decline.
    Peretti DE; Boccalini C; Ribaldi F; Scheffler M; Marizzoni M; Ashton NJ; Zetterberg H; Blennow K; Frisoni GB; Garibotto V
    Brain; 2024 Jun; ():. PubMed ID: 38940331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurogranin in Alzheimer's disease and ageing: A human post-mortem study.
    Saunders T; Gunn C; Blennow K; Kvartsberg H; Zetterberg H; Shenkin SD; Cox SR; Deary IJ; Smith C; King D; Spires-Jones T
    Neurobiol Dis; 2023 Feb; 177():105991. PubMed ID: 36623608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
    Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
    Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain-derived tau: a novel blood-based biomarker for Alzheimer's disease-type neurodegeneration.
    Gonzalez-Ortiz F; Turton M; Kac PR; Smirnov D; Premi E; Ghidoni R; Benussi L; Cantoni V; Saraceno C; Rivolta J; Ashton NJ; Borroni B; Galasko D; Harrison P; Zetterberg H; Blennow K; Karikari TK
    Brain; 2023 Mar; 146(3):1152-1165. PubMed ID: 36572122
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of β-amyloid positivity in Alzheimer's Disease Neuroimaging Initiative participants with demographics, cognition, MRI and plasma biomarkers.
    Tosun D; Veitch D; Aisen P; Jack CR; Jagust WJ; Petersen RC; Saykin AJ; Bollinger J; Ovod V; Mawuenyega KG; Bateman RJ; Shaw LM; Trojanowski JQ; Blennow K; Zetterberg H; Weiner MW
    Brain Commun; 2021; 3(2):fcab008. PubMed ID: 33842885
    [No Abstract]   [Full Text] [Related]  

  • 9. Plasma neurofilament light, glial fibrillary acid protein, and phosphorylated tau 181 as biomarkers for neuropsychiatric symptoms and related clinical disease progression.
    Rabl M; Zullo L; Lewczuk P; Kornhuber J; Karikari TK; Blennow K; Zetterberg H; Bavato F; Quednow BB; Seifritz E; von Gunten A; Clark C; Popp J
    Res Sq; 2024 Mar; ():. PubMed ID: 38562890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time course of phosphorylated-tau181 in blood across the Alzheimer's disease spectrum.
    Moscoso A; Grothe MJ; Ashton NJ; Karikari TK; Rodriguez JL; Snellman A; Suárez-Calvet M; Zetterberg H; Blennow K; Schöll M;
    Brain; 2021 Feb; 144(1):325-339. PubMed ID: 33257949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and biological relevance of glial fibrillary acidic protein in Alzheimer's disease.
    Yang Z; Sreenivasan K; Toledano Strom EN; Osse AML; Pasia LG; Cosme CG; Mugosa MRN; Chevalier EL; Ritter A; Miller JB; Cordes D; Cummings JL; Kinney JW
    Alzheimers Res Ther; 2023 Nov; 15(1):190. PubMed ID: 37924152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
    Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
    Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dissecting phenotypic traits linked to human resilience to Alzheimer's pathology.
    Perez-Nievas BG; Stein TD; Tai HC; Dols-Icardo O; Scotton TC; Barroeta-Espar I; Fernandez-Carballo L; de Munain EL; Perez J; Marquie M; Serrano-Pozo A; Frosch MP; Lowe V; Parisi JE; Petersen RC; Ikonomovic MD; López OL; Klunk W; Hyman BT; Gómez-Isla T
    Brain; 2013 Aug; 136(Pt 8):2510-26. PubMed ID: 23824488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia.
    Abdelnour C; van Steenoven I; Londos E; Blanc F; Auestad B; Kramberger MG; Zetterberg H; Mollenhauer B; Boada M; Aarsland D;
    Mov Disord; 2016 Aug; 31(8):1203-8. PubMed ID: 27296778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Distinct brain pathologies associated with Alzheimer's disease biomarker-related phospho-tau 181 and phospho-tau 217 in
    Hirota Y; Sakakibara Y; Ibaraki K; Takei K; Iijima KM; Sekiya M
    Brain Commun; 2022; 4(6):fcac286. PubMed ID: 36440096
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-sectional and longitudinal evaluation of plasma glial fibrillary acidic protein to detect and predict clinical syndromes of Alzheimer's disease.
    Ally M; Sugarman MA; Zetterberg H; Blennow K; Ashton NJ; Karikari TK; Aparicio HJ; Frank B; Tripodis Y; Martin B; Palmisano JN; Steinberg EG; Simkin I; Farrer LA; Jun GR; Turk KW; Budson AE; O'Connor MK; Au R; Goldstein LE; Kowall NW; Killiany R; Stern RA; Stein TD; McKee AC; Qiu WQ; Mez J; Alosco ML
    Alzheimers Dement (Amst); 2023; 15(4):e12492. PubMed ID: 37885919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neurochemical diversity of dystrophic neurites in the early and late stages of Alzheimer's disease.
    Dickson TC; King CE; McCormack GH; Vickers JC
    Exp Neurol; 1999 Mar; 156(1):100-10. PubMed ID: 10192781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age.
    Betthauser TJ; Koscik RL; Jonaitis EM; Allison SL; Cody KA; Erickson CM; Rowley HA; Stone CK; Mueller KD; Clark LR; Carlsson CM; Chin NA; Asthana S; Christian BT; Johnson SC
    Brain; 2020 Jan; 143(1):320-335. PubMed ID: 31886494
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma tau, neurofilament light chain and amyloid-β levels and risk of dementia; a population-based cohort study.
    de Wolf F; Ghanbari M; Licher S; McRae-McKee K; Gras L; Weverling GJ; Wermeling P; Sedaghat S; Ikram MK; Waziry R; Koudstaal W; Klap J; Kostense S; Hofman A; Anderson R; Goudsmit J; Ikram MA
    Brain; 2020 Apr; 143(4):1220-1232. PubMed ID: 32206776
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.